---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-23-000017"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T23:39:06.952379+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exelixis posts Q4 net loss $30.2M; cabozantinib franchise revenue $1.4B for FY2022

## Summary
- Q4 total revenues $423.9M, down 6% from $451.1M a year ago; cabozantinib U.S. net product revenues $377.4M.
- GAAP diluted EPS $(0.09) for Q4 vs $0.29 in Q4 2021; full year GAAP diluted EPS $0.56 vs $0.72.
- Non-GAAP diluted EPS $(0.03) for Q4 vs $0.35; full year non-GAAP diluted EPS $0.82 vs $1.01.
- R&D expenses rose to $336.8M in Q4 (from $222.3M) on higher license and collaboration costs.
- Company plans to initiate phase 3 studies of zanzalintinib and advance XB002 into full development in 2023.

## SEC filing metadata
- accession: 0000939767-23-000017
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976723000017/0000939767-23-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976723000017/exel-20230207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-23-000017
- JSON: https://secwatch.observer/filing/0000939767-23-000017.json
- Plain text: https://secwatch.observer/filing/0000939767-23-000017.txt

## Key facts
- Earnings Releases
  EXELIXIS, INC. reported the year ended December 31, 2022 results: revenue $1,611.1 million, net income $182.3 million, EPS $0.56 per share, diluted.
  - Period: the year ended December 31, 2022
  - Revenue: $1,611.1 million
  - Net income: $182.3 million
  - EPS: $0.56 per share, diluted
  - Result: reported results
  source text: Total revenues for the quarter and year ended December 31, 2022 were $423.9 million and $1,611.1 million, respectively, as compared to $451.1 million and $1,435.0 million for the comparable periods in 2021. Total revenues for the quarter and year ended December 31, 2022 included net product revenues of $377.4 million and $1,401.2 million, respectively, as compared to $302.7 million and $1,077.3 million for the comparable periods in 2021. The increases in net product revenues were primarily due to increases in sales volume, which were partially offset by higher discounts and allowances, driven primarily by chargebacks related to the 340B Drug Pricing Program. Collaboration revenues, composed of license revenues and collaboration services revenues, were $46.5 million and $209.8 million for the quarter and year ended December 31, 2022, respectively, as compared to $148.5 million and $357.7 million for the comparable periods in 2021. The decreases in collaboration revenues were primarily r
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976723000017/0000939767-23-000017-index.htm
- Earnings Releases
  EXELIXIS, INC. reported the quarter ended December 31, 2022 results: revenue $423.9 million, net income $(30.2) million, EPS $(0.09) per share, basic and diluted.
  - Period: the quarter ended December 31, 2022
  - Revenue: $423.9 million
  - Net income: $(30.2) million
  - EPS: $(0.09) per share, basic and diluted
  - Result: reported results
  source text: Total revenues for the quarter and year ended December 31, 2022 were $423.9 million and $1,611.1 million, respectively, as compared to $451.1 million and $1,435.0 million for the comparable periods in 2021. Total revenues for the quarter and year ended December 31, 2022 included net product revenues of $377.4 million and $1,401.2 million, respectively, as compared to $302.7 million and $1,077.3 million for the comparable periods in 2021. The increases in net product revenues were primarily due to increases in sales volume, which were partially offset by higher discounts and allowances, driven primarily by chargebacks related to the 340B Drug Pricing Program. Collaboration revenues, composed of license revenues and collaboration services revenues, were $46.5 million and $209.8 million for the quarter and year ended December 31, 2022, respectively, as compared to $148.5 million and $357.7 million for the comparable periods in 2021. The decreases in collaboration revenues were primarily r
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976723000017/0000939767-23-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.